Albireo Pharma (ALBO) Gets a Buy Rating from Wedbush

By Jason Carr

Wedbush analyst Liana Moussatos maintained a Buy rating on Albireo Pharma (ALBOResearch Report) today and set a price target of $69.00. The company’s shares closed last Monday at $19.18, close to its 52-week low of $16.13.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -10.3% and a 34.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $55.00, implying a 171.2% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $50.00 price target.

See today’s analyst top recommended stocks >>

Based on Albireo Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.63 million. In comparison, last year the company had a GAAP net loss of $14.03 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.